MiRNA-429 Suppresses the Growth of Gastric Cancer Cells in Vitro

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2013 Apr 5

PMID 23554776

Citations 20

Authors

Di Liu

Peng Xia

Dongmei Diao

Yao Cheng

Hao Zhang

Dawei Yuan

Chen Huang

Chengxue Dang

Affiliations

Soon will be listed here.

Abstract

Micro-RNAs (miRNAs) have been found to be implicated in a very wide range of physiological processes. This study was aimed to investigate the regulation of miRNA-429 (miR-429) in gastric cancer cells on cell proliferation and apoptosis. Quantitative PCR was employed to detect the expressions of miR-429 after eukaryotic expression plasmid of miR-429 and its inhibitor were transiently transfected into poorly differentiated human gastric cancer cell line BGC823. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assays were used to examine proliferation ability. Apoptosis was analyzed by flow cytometry after transfection. The results showed that 48 h after transfection, overexpression of miR-429 reached maximum efficiency. Compared with mock transfection, miR-429 inhibited tumor cell proliferation significantly (P < 0.05) at 48 h and 72 h. of Overexpression of miR-429 promoted tumor cell apoptosis when compared with mock transfected cells (P < 0.05). On the contrary, miR-429 inhibitor promoted tumor cell proliferation and inhibited apoptosis when compared with controls (P < 0.05). Our results suggested that miRNA-429 may serve as a tumor suppressor during tumorigenesis of gastric cancer and may be a potential gastric cancer therapeutic target.

Citing Articles

The role of miR-200 family in the regulation of hallmarks of cancer.

Klicka K, Grzywa T, Mielniczuk A, Klinke A, Wlodarski P Front Oncol. 2022; 12:965231.

PMID: 36158660 PMC: 9492973. DOI: 10.3389/fonc.2022.965231.

Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429.

Sun Y, Hou Z, Luo B, Li C, Liu J, Liu J Bioengineered. 2021; 12(1):4159-4173.

PMID: 34288815 PMC: 8806410. DOI: 10.1080/21655979.2021.1953822.

The inhibiting effects of microRNA-429 on the progression of pancreatic ductal adenocarcinoma cells by inhibiting epithelial mesenchymal transition.

Chen D, Zhao H Am J Transl Res. 2021; 13(4):3286-3293.

PMID: 34017500 PMC: 8129377.

Linc00641 promotes the progression of gastric carcinoma by modulating the miR-429/Notch-1 axis.

Hang Q, Lu J, Zuo L, Liu M Aging (Albany NY). 2021; 13(6):8497-8509.

PMID: 33714199 PMC: 8034904. DOI: 10.18632/aging.202661.

MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-κB pathway.

Zhou X, Lu H, Li F, Hao X, Han L, Dong Q Cell Mol Biol Lett. 2020; 25:5.

PMID: 32082390 PMC: 7020518. DOI: 10.1186/s11658-020-0202-9.

References

Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y, Ngankeu A . EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011; 18(1):74-82. PMC: 3467100. DOI: 10.1038/nm.2577. View

Saini S, Majid S, Yamamura S, Tabatabai L, Suh S, Shahryari V . Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res. 2010; 17(16):5287-98. DOI: 10.1158/1078-0432.CCR-10-2619. View

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

Hu X, Macdonald D, Huettner P, Feng Z, El Naqa I, Schwarz J . A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009; 114(3):457-64. DOI: 10.1016/j.ygyno.2009.05.022. View

Si M, Zhu S, Wu H, Lu Z, Wu F, Mo Y . miR-21-mediated tumor growth. Oncogene. 2006; 26(19):2799-803. DOI: 10.1038/sj.onc.1210083. View

Lawrie C, Gal S, Dunlop H, Pushkaran B, Liggins A, Pulford K . Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5):672-5. DOI: 10.1111/j.1365-2141.2008.07077.x. View

Pang R, Leung C, Ye T, Liu W, Chiu P, Lam K . MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010; 31(6):1037-44. DOI: 10.1093/carcin/bgq066. View

Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou C . A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance. PLoS One. 2011; 6(12):e29043. PMC: 3237583. DOI: 10.1371/journal.pone.0029043. View

10.

Fabian M, Sonenberg N, Filipowicz W . Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010; 79:351-79. DOI: 10.1146/annurev-biochem-060308-103103. View

11.

Lin S, Chang D, Ying S, Leu D, Wu D . MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010; 70(22):9473-82. DOI: 10.1158/0008-5472.CAN-10-2746. View

12.

Sempere L . Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn. 2011; 11(8):813-27. PMC: 3220160. DOI: 10.1586/erm.11.69. View

13.

Lima R, Busacca S, Almeida G, Gaudino G, Fennell D, Vasconcelos M . MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2010; 47(2):163-74. DOI: 10.1016/j.ejca.2010.11.005. View

14.

Van Rooij E . The art of microRNA research. Circ Res. 2011; 108(2):219-34. DOI: 10.1161/CIRCRESAHA.110.227496. View

15.

Davis-Dusenbery B, Hata A . MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways. Genes Cancer. 2011; 1(11):1100-14. PMC: 3083114. DOI: 10.1177/1947601910396213. View

16.

Tryndyak V, Beland F, Pogribny I . E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2009; 126(11):2575-83. DOI: 10.1002/ijc.24972. View

17.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

18.

Fabian M, Sundermeier T, Sonenberg N . Understanding how miRNAs post-transcriptionally regulate gene expression. Prog Mol Subcell Biol. 2009; 50:1-20. DOI: 10.1007/978-3-642-03103-8_1. View

19.

Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O . miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011; 17(12):1627-35. DOI: 10.1038/nm.2512. View

20.

Borralho P, Simoes A, Gomes S, Lima R, Carvalho T, Ferreira D . miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PLoS One. 2011; 6(8):e23787. PMC: 3162002. DOI: 10.1371/journal.pone.0023787. View